/
ENVB
$1.50-$0.01 (-0.99%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$6.2M
4M shares
52-week range
$1.25 – $17.64
1% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-14488.50
Enveric Biosciences, Inc. Common Stock
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
www.enveric.com- Employees
- 6
- IPO / List date
- Aug 24, 1995
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds ENVB.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ENVB as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-10-28 | 1-for-12reverse |
| 2025-01-29 | 1-for-15reverse |
| 2022-07-15 | 1-for-50reverse |
| 2019-11-25 | 1-for-25reverse |
Recent trades on TradeandTell
No one on the platform has traded ENVB yet.
